Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAM: Afatinib Diarrhea Management in EGFR+ NSCLC
NCT01814553Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of afatinib in lung adenocarcinoma (LUAD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of CTCAE Grade >= 2 Diarrhea at 84 days. Started Apr 2013; status: completed.
02
Drugs
afatinib
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT01814553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01814553.